A phase 2 randomised, open-label, multi-centre ascending dose study of the efficacy, safety and tolerability of I-040302 versus control injection (bone marrow aspirate or steroids) in children and young adults with solitary bone cysts.

Trial Profile

A phase 2 randomised, open-label, multi-centre ascending dose study of the efficacy, safety and tolerability of I-040302 versus control injection (bone marrow aspirate or steroids) in children and young adults with solitary bone cysts.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs KUR 112 (Primary) ; Methylprednisolone
  • Indications Bone cysts
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jul 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Planned initiation date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Planned end date changed from 1 Jul 2018 to 1 Jul 2019 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top